Anemia in patients on combined androgen block therapy for prostate cancer / 亚洲男科学杂志(英文版)
Asian Journal of Andrology
;
(6): 383-384, 2004.
Artigo
em Inglês
| WPRIM
| ID: wpr-270880
ABSTRACT
<p><b>AIM</b>To study the effect of combined androgen block therapy on hemoglobin and hematocrit values in patients with prostate cancer.</p><p><b>METHODS</b>One hundred and thirty-six patients with adenocarcinoma of prostate were treated with combined androgen block (orchiectomy and flutamide 250 mg, tid). Complete blood counts were determined before and after 1, 2, 3, 6, 9 and 12 months of therapy.</p><p><b>RESULTS</b>The hemoglobin and hematocrit levels declined significantly in all patients and at all the time points after treatment (P<0.05).</p><p><b>CONCLUSION</b>Prostate cancer patients treated with combined androgen block would develop obvious anemia. Recombinant human erythropoietin can be used to treat patients with severe anemia.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias da Próstata
/
Terapêutica
/
Hemoglobinas
/
Orquiectomia
/
Adenocarcinoma
/
Terapia Combinada
/
Antineoplásicos Hormonais
/
Proteínas Secretadas pela Próstata
/
Usos Terapêuticos
/
Tratamento Farmacológico
Limite:
Adulto
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Asian Journal of Andrology
Ano de publicação:
2004
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS